DZDavid Zargaran

David Zargaran

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


David Zargaran has a total of 61 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Efficiency and Sustainability in the Skin Cancer Excision Pathway: Life Cycle Assessment and Process Map

    by Zahra Ahmed, Alexander Zargaran, Sara Moeini, Sara Sousi, David Zargaran, Ann-Marie Quigley, Norbert Kang, Afshin Mosahebi

    Background: Skin cancer is the most commonly diagnosed cancer. In secondary care, patients enter a complex pathway, often involving excision. This multistage process likely has a significant carbon footprint, which has not been previously evaluated. Objective: The aims of this study were to quantify the carbon footprint of the skin cancer excision pathway and to identify opportunities for pathway optimization to improve both sustainability and efficiency. Methods: A retrospective process mapping and life cycle analysis of 64 patients undergoing skin cancer excision were performed for patient-facing and organizational steps from diagnosis to follow-up. Estimates for carbon dioxide emissions and areas for pathway remodeling were generated. Results: The carbon footprint of a patient undergoing skin cancer excision was 118.5 kg carbon dioxide equivalent (CO2eq). The perioperative phase had the highest emissions (53.1 kgCO2eq, 44.8%), but the combined diagnostic and follow-up periods had greater emissions (65.4 kgCO2eq, 55.2%). Imaging and nuclear medicine were responsible for over a third of emissions (42.5 kgCO2eq, 35.9%). Conclusions: This is the first study to evaluate the carbon footprint of the secondary care skin cancer excision pathway. Multiple inefficiencies were identified, and opportunities for improvement, pathway stratification, diagnostic justification, and adoption of circular economy principles were suggested to increase sustainability and improve standards of care.

  • Open Access

    Global Pharmacovigilance of Aesthetic Botulinum Toxin Type A: Analysis of Adverse Event Reports From the USA , Europe, Canada, and Australia

    by Alexander Zargaran, David Zargaran, Ali Pirayesh, Alex Woollard, Afshin Mosahebi

    Background: Monitoring of adverse events for aesthetic BoNT‐A (BoNT‐A) through pharmacovigilance databases provides critical insight into real‐world safety profiles. Previous analyses suggested substantial underreporting, yet comprehensive international multi‐database analysis remains absent. Methods: Adverse event reports for aesthetic BoNT‐A indications were extracted from FDA FAERS, EMA EudraVigilance, Health Canada MedEffect, and TGA DAEN databases from 2002 to 2025. Reports were filtered for cosmetic indications using procedure codes, anatomical sites, and indication descriptions. Events were categorized by clinical manifestation and severity using MedDRA classification. Results: Analysis identified 43,809 adverse event reports across four databases. FDA FAERS contributed 38,321 reports (87.5%), EudraVigilance 3,526 (8.0%), Health Canada 1,835 (4.2%), and TGA DAEN 127 (0.3%). Effectiveness issues comprised 57.3% of reports ( n = 25,092), followed by local injection‐site reactions (19.7%, n = 8,611), facial paresis/ptosis/asymmetry (9.9%, n = 4,348), and headache (6.0%, n = 2,650). Peak reporting occurred in 2018 for FAERS (1,375 reports) and 2020 for Health Canada (242 reports). Among FAERS reports with brand attribution, onabotulinumtoxinA accounted for 86.8%, abobotulinumtoxinA 9.7%, and incobotulinumtoxinA 2.4%. Co‐reported adverse event analysis revealed drug ineffective with therapeutic response decreased as the most frequent pairing ( n = 2,947), followed by drug ineffective with off‐label use ( n = 1,102). Conclusions: The predominance of effectiveness issues over traditional safety concerns distinguishes aesthetic BoNT‐A pharmacovigilance from typical pharmaceutical surveillance. Geographic concentration of reporting in the United States despite global market distribution indicates systematic underreporting internationally. These findings suggest current pharmacovigilance systems inadequately capture aesthetic medicine adverse events, with direct implications for patient safety and regulatory oversight.


  • Open Access

    Mapping the UK Aesthetic Medicine Industry: Practitioner Profiles, Pricing, and Socioeconomic Gradients in Botulinum Toxin Practice

    by Alexander Zargaran, David Zargaran, Hamid Reza Khademi Mansour, Lara Turan, Giulia Bocciardi, Yichen Liu, Anita Golash, Kian Daneshi, Ali Pirayesh, Alex Woollard, et al.

    Background: The United Kingdom aesthetic botulinum toxin industry operates with limited regulatory oversight despite being a prescription-only medication. Following recent public scrutiny, regulatory reforms are imminent, warranting comprehensive analysis to inform evidence-based policy. Objectives: The aim of the study was to characterize practitioner profiles, pricing patterns, premises types, and socioeconomic gradients in the provision of aesthetic botulinum toxin across the United Kingdom. Methods: Cross-sectional analysis was conducted of practitioners administering aesthetic botulinum toxin and fillers across the UK (January–July 2025). Data were collected from publicly available websites and social media platforms. Geographic analysis used deprivation indices to examine socioeconomic patterns. Statistical methods included descriptive analysis, χ2 tests, and multivariable regression modeling. Results: A total of 19,701 practitioners across 5589 clinics were identified, representing a 437% increase over 2 years. Doctors comprised 28.4% of practitioners, while the proportion of nonmedical aestheticians doubled from 12% to 24.8%. Practitioner density showed a 6.7-fold increase from the least (9.4 per 100,000) to the most deprived areas (63.2 per 100,000). Doctor representation declined from 34.4% in affluent areas to 27.0% in deprived areas, while odds of nonclinical botulinum toxin administering beauty salon exposure peaked in moderately deprived areas (odds ratio [OR] = 2.18). Specialist access (dermatologists/plastic surgeons) declined significantly in Quintiles 3 to 5 (ORs 0.70-0.77). Regression analysis identified practitioner profession as the strongest pricing determinant: doctors charged 32% to 38% more than aestheticians, dentists 28% to 33% more, and nurses 2% to 4% more (all P < .001). Geographic context exerted modest effects, with higher-income and denser areas associated with 1% to 5% higher prices. Conclusions: The UK aesthetic medicine market has expanded rapidly, with significant differences in practitioner qualifications and treatment settings across socioeconomic groups. These findings provide key evidence to guide upcoming regulatory reforms and highlight the need for stronger safety oversight of prescription-only aesthetic procedures. Level of Evidence: 5 (Therapeutic):


  • Open Access

    Esthetic Clinic Management Software—Can we improve patient safety?

    by Jessica Kamal, David Zargaran, Alexander Zargaran, Afshin Mosahebi

  • Open Access

    Quantitative and Qualitative Analysis of Individual Experiences Post Botulinum Toxin Injection - United Kingdom Survey

    by David Zargaran, Alexander Zargaran, Sara Sousi, Dawn Knight, Hannah Cook, Alexander Woollard, Julie Davies, Tim Weyrich, Afshin Mosahebi

    Introduction: In the United Kingdom (UK), complications that arise following the administration of Botulinum Toxin are reported to the Medicines and Health Regulatory Agency (MHRA) via the Yellow Card Reporting Scheme. Over the past decade, there has been a significant increase in the number of non-surgical aesthetic procedures. Concerns have been raised that the MHRA is not fully capturing complications in terms of volume and impact on patients. Aim: This novel study explores the lived experiences of individuals who have experienced an adverse event following administration of Botulinum Toxin for aesthetic purposes. Using a combination of qualitative and quantitative methodologies, this analysis evaluates data relating to long-lasting physical, psychological, emotional, and financial sequelae of complications arising from cosmetic Botulinum Toxin injections in the UK. Methods: A mixed method, qualitative and quantitative approach was adopted to gain comprehensive insights into patients' experiences. A focus group which comprised patient representatives, psychologists, and researchers reached a consensus on a 17-question survey which was disseminated via social media channels. Deductive thematic analysis was used to analyse coded themes. Furthermore, for secondary analysis, sentiment analysis was used computationally as an innovative approach to identify and categorise free text responses associated with sentiments using natural language processing (NLP). Results: In the study, 655 responses were received, with 287 (44%) of respondents completing all questions. The mean age of respondents was 42.6 years old. 94.1% of respondents identified as female. In the sample, 79% of respondents reported an adverse event following their procedure, with the most common event being reported as ‘anxiety’. Findings revealed that 69% of respondents reported long-lasting adverse effects. From the responses, 68.4% reported not having recovered physically, 63.5% of respondents stated that they had not recovered emotionally from complications, and 61.7% said that they have not recovered psychologically. In addition, 84% of respondents stated that they do not know who regulates the aesthetics industry. Furthermore, 92% of participants reported that their clinic or practitioner did not inform them about the Yellow Card Reporting Scheme. The sentiment analysis using the AFINN Lexicon yielded adjusted scores ranging from −3 to +2, with a mean value of −1.58. Conclusion: This is the largest survey in the UK completed by patients who experienced an adverse outcome following the aesthetic administration of Botulinum Toxin. Our study highlights the extent of the challenges faced by patients who experience an adverse event from physical, emotional, psychological, and financial perspectives. The lack of awareness of MHRA reporting structures and the lack of regulation within the UK's cosmetic injectables sector represent a significant public health challenge.


  • Open Access

    Profiling UK injectable aesthetic practitioners: A national cohort analysis

    by David Zargaran, Alexander Zargaran, Tom Terranova, Helia Khaledi, Alexandra Robinson, Julie Davies, Tim Weyrich, Afshin Mosahebi


  • Open Access

    O165 Cosmetic business mechanics in London: a cross sectional analysis and audit of ASA compliance

    by D Zargaran, A Zargaran, S Sousi, A Woollard, J Davies, T Weyrich, A Mosahebi

    Introduction: We aim to perform a cross-sectional analysis of the practitioners in London, UK to evaluate the distribution of clinics within the Greater London, prices advertised for interventions, and compliance with the Advertising Standards Authority (ASA) legislation. We also aim to identify whether there are any differences in cost of Botulinum Toxin or Dermal Filler between the boroughs. Methods: Between December 2021 and January 2022, we performed a systematic search using the internet search engine Google. Any reference to Botulinum Toxin or anti-wrinkle injections was noted and analysed. Further analysis would look to calculate price per millilitre (ml) of Botulinum Toxin and Dermal Filler per borough and to calculate whether there were any statistical differences between the 32 different London boroughs. Results: A total of 500 websites were visited and evaluated. A total of 233 independent clinics were identified. 206/233 clinics sampled – 88% were in direct infringement of the enforcement notice through advertising a prescription medicine. The overall average cost per ml of Dermal Filler was £330.89 and there was a statically significant variance(p<0.05). The overall average cost per ml of Botulinum Toxin was £284.45 and the variance across boroughs was p=0.058. Conclusion: This paper demonstrates poor compliance with the ASA guidelines and identifies regional variance in price and clinic density. The advertising of prescription only medication may pose a potential risk to patients and will be an important consideration in proposed legislation to introduce licensing to the industry.